## SDGR: Schrodinger, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.0% below STRENGTH zone (3.0-6.0%); PEG 1.30 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.6% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($16.02)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Schrodinger, Inc. (NASDAQ:SDGR) Given Consensus Rating of "Hold" by Brokerages**
- Source: MarketBeat | 20251218T080913 | Neutral | Relevance: 100%
- Schrodinger, Inc. (NASDAQ:SDGR) has received a consensus "Hold" rating from various brokerage firms, with an average 1-year price target of $25.71. Despite beating revenue and EPS estimates in its latest quarter, the company remains unprofitable. Institutional investors and insiders hold significant stakes in SDGR, which has recently seen some analyst rating adjustments.

**2. Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)**
- Source: PharmiWeb.com | 20251217T170913 | Neutral | Relevance: 100%
- Schrödinger, Inc. (Nasdaq: SDGR) announced that on December 15, 2025, it granted restricted stock units (RSUs) for 2,666 shares of common stock to 6 new employees. These grants were made under the company’s 2021 Inducement Equity Incentive Plan, approved by the compensation committee, and serve as a material inducement for their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years, with 25% vesting after 12 months and the remainder in equal yearly installments over the subsequent three years.

**3. Schrödinger reports inducement grants under Nasdaq listing**
- Source: marketscreener.com | 20251217T150913 | Neutral | Relevance: 100%
- Schrödinger, Inc. (NASDAQ:SDGR) has reported inducement grants under Nasdaq Listing Rule 5635(c)(4). This news, published by Reuters, indicates compliance with Nasdaq regulations regarding employee compensation. The company develops a physics-based computational platform for drug development and materials applications.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | B of A Securiti | $24 | $24 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | B of A Securiti | up | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.03M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 70.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Blackrock Inc.: 14.8% (-2.2%)
- Gates Foundation Tru: 10.8% (0.0%)
- Vanguard Group Inc: 9.8% (-4.2%)
- Rubric Capital Manag: 8.2% (+5.4%)
- Sumitomo Mitsui Trus: 7.1% (+24.8%)

### Key Risks

1. High short interest (25.5%, 10.0 days to cover): squeeze risk or crowded bearish bet.
2. Long-term trend broken: trading 15.0% below SMA200.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.30 suggests fair value with growth premium. Balance sheet: strong liquidity (3.2x). Revenue growth strong at 20% YoY. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $1.3B |
| Beta | 1.57 |
| 52W Range | $15.99 - $28.47 |
| Short Interest | 25.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.30 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 deteriorating from 3.6% to -1.0% (-4.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.0pp (needs >3.0% for momentum thesis). Below SMA200 (0.85x), long-term trend not supportive. RSI neutral at 47. OFD pattern: +MTH (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.97% (CS: 35) | Neutral |
| RSI_14 | 47.0 | Neutral |
| MACD Histogram | 0.06 | Bullish |
| vs SMA20 | 1.003x | Above |
| vs SMA50 | 0.940x | Below |
| vs SMA200 | 0.850x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $17.66
- **Stop Loss:** $16.02 (9.3% risk)
- **Target:** $19.30 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 731
- **Position Value:** $12,909.46
- **Portfolio %:** 12.91%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-25 (Est: $-0.17)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.74 | $-0.57 | +23.0% |
| 2025Q2 | $-0.64 | $-0.65 | -1.6% |
| 2025Q1 | $-0.81 | $-0.64 | +21.0% |
| 2024Q4 | $-0.38 | $-0.24 | +36.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*